Genenta Science S.p.A. (GNTA)

NASDAQ: GNTA · IEX Real-Time Price · USD
6.28
+0.33 (5.55%)
Feb 6, 2023, 10:56 AM EST - Market open

Company Description

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.

It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.

The company was incorporated in 2014 and is headquartered in Milan, Italy.

Genenta Science S.p.A.
Genenta Science S.p.A. logo
Country Italy
Founded 2014
IPO Date Dec 15, 2021
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Mr. Pierluigi Paracchi

Contact Details

Address:
Olgettina, No. 58
Milan, L6 20132
Italy
Phone 39-02-2643-6639
Website genenta.com

Stock Details

Ticker Symbol GNTA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency EUR
IPO Price $11.50
CIK Code 0001838716
CUSIP Number 36870W100
ISIN Number US36870W1009
SIC Code 2836

Key Executives

Name Position
Pierluigi Paracchi Vice Chairman, Chief Executive Officer and GM
Dr. Luigi Naldini M.D., Ph.D. Co-Founder and Chairman of the Executive Scientific Board
Dr. Bernard Rudolph Gentner M.D., Ph.D. Co-Founder and Member of the Executive Scientific Board
Richard B. Slansky Chief Financial Officer
Dr. Stefania Mazzoleni Ph.D. Scientific Director and Communication Officer
Dr. Carlo Russo M.D. Chief Medical Officer and Head of Development
Tim Obara Head of Business Development

Latest SEC Filings

Date Type Title
Feb 1, 2023 6-K Report of foreign issuer
Dec 22, 2022 6-K Report of foreign issuer
Dec 15, 2022 6-K Report of foreign issuer
Oct 25, 2022 6-K Report of foreign issuer
Oct 25, 2022 6-K Report of foreign issuer
Oct 3, 2022 6-K Report of foreign issuer
Jun 14, 2022 6-K Report of foreign issuer
May 11, 2022 6-K Report of foreign issuer
May 2, 2022 20-F Annual and transition report of foreign private issuers
Feb 25, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals